Previous 10 | Next 10 |
December 10, 2019 Palm Beach, FL –December 10, 2019 – There are so many paths that R&D is taking in the ongoing fight against cancer. New drugs, new therapies and new techniques are developed to help researchers and practitioners across all cancer sub-markets. One su...
SOUTH SAN FRANCISCO, Calif. , Dec. 10, 2019 /PRNewswire/ -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced ...
Gainers: Astrotech Corporation (NASDAQ: ASTC ) +87% . More news on: Astrotech Corporation, Pier 1 Imports, Inc., Celsion Corporation, Stocks on the move, Read more ...
Thinly traded nano cap VistaGen Therapeutics ( VTGN -67% ) craters on more than a 9x surge in volume after AV-101 failed to separate from placebo in a Phase 2 clinical trial, ELEVATE , evaluating the candidate for the adjunctive treatment of major depressive disorder. More news on: Vi...
VistaGen Therapeutics (NASDAQ: VTGN ) -67% on reporting Phase 2 results for AV-101 as a treatment of major depressive disorder. More news on: VistaGen Therapeutics, Inc., Pacific Coast Oil Trust, Ideanomics, Inc., Stocks on the move, Read more ...
SOUTH SAN FRANCISCO, Calif. , Nov. 14, 2019 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced topline res...
SOUTH SAN FRANCISCO, Calif. , Nov. 7, 2019 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced financial re...
Company Thesis VistaGen Therapeutics (VTGN) is a small-cap biotech company currently possessing 3 drug candidates in clinical trials for various psychiatric indications. Out of the 3 candidates, both PH94B indicated for social anxiety disorder and AV-101 indicated for major depressive di...
SOUTH SAN FRANCISCO, Calif. , Oct. 28, 2019 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced that t...
Investment Thesis Backed by positive results from a phase 02 trial for Major Depressive Disorder ((MDD)), the shares of Axsome Therapeutics, Inc. ( AXSM ) have jumped nearly seven times in 2019 so far. Out of the six clinical trials currently in progress, four data readouts will be availab...
News, Short Squeeze, Breakout and More Instantly...
VistaGen Therapeutics Inc. Company Name:
VTGN Stock Symbol:
NASDAQ Market:
VistaGen Therapeutics Inc. Website:
Vistagen Therapeutics (NASDAQ: VTGN ), a clinical-stage, neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, has received multiple new patent...
Vistagen (Nasdaq: VTGN), a clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced the broadening of its global in...
Vistagen (NASDAQ: VTGN) , a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it has been recognized by Mental Health America (“MHA”) for its dedication to pr...